Human African trypanosomiasis: Pharmacological re-engagement with a neglected disease

British Journal of Pharmacology

Volumn 152, Issue 8, 2007, Pages 1155-1171

  Barrett, M P ^a   Boykin, D W ^b   Brun, R ^c   Tidwell, R R ^d  

^a UNIVERSITY OF GLASGOW   (United Kingdom)

^b GEORGIA STATE UNIVERSITY   (United States)

^c SWISS TROPICAL AND PUBLIC HEALTH INSTITUTE   (Switzerland)

^d UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

Eflornithine; Furamidine; Human African trypanosomiasis; Melarsoprol; Neglected disease; Nifurtimox; Pafuramidine; Pentamidine; Sleeping sickness; Suramin

Indexed keywords

DIMINAZENE; EFLORNITHINE; MELARSOPROL; NIFURTIMOX; PAFURAMIDINE; PENTAMIDINE; PENTAMIDINE ISETHIONATE; SURAMIN;

AFRICAN TRYPANOSOMIASIS; ANEMIA; ANTIBIOTIC RESISTANCE; BLOOD CLOTTING DISORDER; BRAIN INFECTION; CLINICAL TRIAL; CONVULSION; DIARRHEA; DISEASE COURSE; DRUG HALF LIFE; DRUG MECHANISM; DRUG METABOLISM; FATIGUE; FEVER; GASTROINTESTINAL SYMPTOM; HEADACHE; HEART FAILURE; HUMAN; HYPERGLYCEMIA; HYPERTENSION; HYPOCALCEMIA; HYPOTENSION; INJECTION SITE PAIN; KIDNEY FAILURE; LEUKOPENIA; NAUSEA; NEPHROTOXICITY; NEUROPATHY; NEUROTOXICITY; NEUTROPENIA; NONHUMAN; PERIPHERAL NEUROPATHY; POLYNEUROPATHY; PRIORITY JOURNAL; PRURITUS; RASH; REVIEW; SIDE EFFECT; SLEEP DISORDER; THROMBOCYTOPENIA; TREATMENT FAILURE; TREATMENT OUTCOME; TREATMENT RESPONSE; TREMOR; VOMITING;

ANIMALS; CENTRAL NERVOUS SYSTEM; CLINICAL TRIALS AS TOPIC; DRUG DELIVERY SYSTEMS; DRUG DESIGN; HUMANS; TIME FACTORS; TRYPANOCIDAL AGENTS; TRYPANOSOMA BRUCEI GAMBIENSE; TRYPANOSOMA BRUCEI RHODESIENSE; TRYPANOSOMIASIS, AFRICAN;

EID: 35548959525     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1038/sj.bjp.0707354     Document Type: Review

References (213)

1. Allsopp R (2001). Options for vector control against trypanosomiasis in Africa. Trends Parasitol 17: 15-19.
2. Anonymous (2006). Human African trypanosomiasis (sleeping sickness): epidemiological update. Wkly Epidemiol Rec 81: 71-80.
3. Ansede JH, Anbazhagan M, Brun R, Easterbrook JD, Hall JE, Boykin DW (2004). O-alkoxyamidine prodrugs of furamidine: in vitro transport and microsomal metabolism as indicators of in vivo efficacy in a mouse model of Trypanosoma brucei rhodesiense infection. J Med Chem 47: 4335-4338.
4. Ansede JH, Voyksner RD, Ismail MA, Boykin DW, Tidwell RR, Hall JE (2005). In vitro metabolism of an orally active O-methyl amidoxime prodrug for the treatment of CNS trypanosomiasis. Xenobiotica 35: 211-226.
5. Apted FIC (1970). Treatment of human trypanosomiasis (Chapter 36). In: Mulligan HW(ed). The African Trypanosomiases. Allen & Unwin Ltd: London, pp 684-710.
6. Atouguia JM, Jennings FW, Murray M (1995). Successful treatment of experimental murine Trypanosoma brucei infection with topical melarsoprol gel. Trans R Soc Trop Med Hyg 89: 531-533.
7. Bacchi CJ, Garofalo J, Ciminelli M, Rattendi D, Goldberg B, McCann PP et al. (1993). Resistance to DL-alpha-difluoromethylornithine by clinical isolates of Trypanosoma brucei rhodesiense. Role of S-adenosylmethionine. Biochem Pharmacol 46: 471-481.
8. Bacchi CJ, Nathan HC, Hutner SH (1980). Polyamine metabolism - a potential therapeutic target in trypanosomes. Science 210: 332-334.
9. Bacchi CJ, Yarlett N (1993). Effects of antagonists of polyamine metabolism on African trypanosomes. Acta Trop 54: 225-236.
10. Balasegaram M, Harris S, Checchi F, Ghorashian S, Hamel C, Karunakara U (2006). Melarsoprol versus eflornithine for treating late-stage Gambian trypanosomiasis in the Republic of the Congo. Bull World Health Organ 84: 783-791.
11. Baliani A, Bueno GJ, Stewart ML, Yardley V, Brun R, Barrett MP et al. (2005). Design and synthesis of a series of melamine-based nitroheterocycles with activity against trypanosomatid parasites. J Med Chem 48: 5570-5579.
12. Barrett MP (1999). The fall and rise of sleeping sickness. Lancet 353: 1113-1114.
13. Barrett MP (2000). Problems for the chemotherapy of human African trypanosomiasis. Curr Opin Infect Dis 13: 647-651.
14. Barrett MP (2001). Veterinary link to drug resistance in human African trypanosomiasis? Lancet 358: 603-604.
15. Barrett MP (2003). Drug resistance in sleeping sickness. WHO expert committee on African trypanosomiasis (sleeping sickness). pp 96-111.
16. Barrett MP (2006). The rise and fall of sleeping sickness. Lancet 367: 1377-1378.
17. Barrett MP, Burchmore RJS, Stich A, Lazzari JO, Frasch AC, Cazzulo JJ et al. (2003). The trypanosomiases. Lancet 362: 1469-1480.
18. Barrett MP, Fairlamb AH (1999). The biochemical basis of arsenical-diamidine crossresistance in African trypanosomes. Parasitol Today 15: 136-140.
19. Barrett MP, Gilbert IH (2006). Targeting of toxic compounds to the trypanosome's interior. Adv Parasitol 63: 126-183.
20. Barrett MP, Mottram JC, Coombs GH (1999). Recent advances in identifying and validating drug targets in trypanosomes and leishmanias. Trends Microbiol 7: 82-88.
21. Barrett MP, Zhang ZQ, Denise H, Giroud C, Baltz T (1995). A diamidine-resistant Trypanosoma equiperdum clone contains a P2 purine transporter with reduced substrate affinity. Mol Biochem Parasitol 73: 223-229.
22. Basselin M, Denise H, Coombs GH, Barrett MP (2002). Resistance to pentamidine in Leishmania mexicana involves exclusion of the drug from the mitochondrion. Antimicrob Agents Chemother 46: 3731-3738.
23. Basselin M, Robert-Gero M (1998). Alterations in membrane fluidity, lipid metabolism, mitochondrial activity, and lipophosphoglycan expression in pentamidine-resistant leishmania. Parasitol Res 84: 78-83.
24. Bastin P, Stephan A, Raper J, SaintRemy JM, Opperdoes FR, Courtoy PJ (1996). An M(r) 145000 low-density lipoprotein (LDL)-binding protein is conserved throughout the Kinetoplastida order. Mol Biochem Parasitol 76: 43-56.
25. Bellofatto V, Fairlamb AH, Henderson GB, Cross GAM (1987). Biochemical-changes associated with alpha-difluoromethylornithine uptake and resistance in Trypanosoma brucei. Mol Biochem Parasitol 25: 227-238.
26. Berger BJ, Carter NS, Fairlamb AH (1993). Polyamine and pentamidine metabolism in African trypanosomes. Acta Trop 54: 215-224.
27. Berger BJ, Carter NS, Fairlamb AH (1995). Characterization of pentamidine-resistant Trypanosoma brucei brucei. Mol Biochem Parasitol 69: 289-298.
28. Berger BJ, Lombardy RJ, Marbury GD, Bell CA, Dykstra CC, Hall JE et al. (1990). Metabolic N-hydroxylation of pentamidine in vitro. Antimicrob Agents Chemother 34: 1678-1684.
29. Berger BJ, Naiman NA, Hall JE, Peggins J, Brewer TG, Tidwell RR (1992). Primary and secondary metabolism of pentamidine by rats. Antimicrob Agents Chemother 36: 1825-1831.
30. Berger BJ, Reddy VV, Le ST, Lombardy RJ, Hall JE, Tidwell RR (1991). Hydroxylation of pentamidine by rat liver microsomes. J Pharmacol Exp Ther 256: 883-889.
31. Berriman M, Ghedin E, Hertz-Fowler C, Blandin G, Renauld H, Bartholomeu DC et al. (2005). The genome of the African trypanosome Trypanosoma brucei. Science 309: 416-422.
32. Besteiro S, Barrett MP, Rivière L, Bringaud F (2005). Energy generation in insect stages of Trypanosoma brucei: metabolism in flux. Trends Parasitol 21: 185-191.
33. Bitonti AJ, Bacchi CJ, McCann PP, Sjoerdsma A (1986a). Uptake of alpha-difluoromethylornithine by Trypanosoma brucei brucei. Biochem Pharmacol 35: 351-354.
34. Bitonti AJ, Mccann PP, Sjoerdsma A (1986b). Necessity of antibody-response in the treatment of African trypanosomiasis with alpha-difluoromethylornithine. Biochem Pharmacol 35: 331-334.
35. Bitton RJ, Figg WD, Venzon DJ, Dalakas MC, Bowden C, Headlee D et al. (1995). Pharmacologic variables associated with the development of neurologic toxicity in patients treated with suramin. J Clin Oncol 13: 2223-2229.
36. Blum J, Nkunku S, Burri C (2001). Clinical description of encephalopathic syndromes and risk factors for their occurrence and outcome during melarsoprol treatment of human African trypanosomiasis. Trop Med Int Health 6: 390-400.
37. Blum J, Schmid C, Burri C (2006). Clinical aspects of 2541 patients with second stage human African trypanosomiasis. Acta Trop 97: 55-64.
38. Bouteille B, Millet P, Enanga B, Mezui Me J, Keita M, Jauberteau MO et al. (1998). Human African trypanosomiasis, contributions of experimental models. Bull Soc Pathol Exot 91: 127-132.
39. Boykin DW, Kumar A, Hall JE, Bender BC, Tidwell RR (1996). Anti-Pneumocystis activity of bis-amidoximes and bis-O-alkylamidoxime prodrugs. Bioorg Med Chem Lett 6: 3017-3020.
40. Bray PG, Barrett MP, Ward SA, de Koning HP (2003). Pentamidine uptake and resistance in pathogenic protozoa: past, present and future. Trends Parasitol 19: 232-239.
41. Bridges DJ, Gould MK, Nerima B, Maeser P, Burchmore RJ, de Koning HP (2007). Loss of the high affinity pentamidine transporter is responsible for high levels of cross-resistance between arsenical and diamidine drugs in African trypanosomes. Mol Pharmacol 71: 1098-1108.
42. Bronner U, Brun R, Doua F, Ericsson O, Burri C, Keiser J et al. (1998). Discrepancy in plasma melarsoprol concentrations between HPLC and bioassay methods in patients with T. gambiense sleeping sickness indicates that melarsoprol is metabolized. Trop Med Int Health 3: 913-917.
43. Bronner U, Doua F, Ericsson O, Gustafsson LL, Miezan TW, Rais M et al. (1991). Pentamidine concentrations in plasma, whole blood and cerebrospinal fluid during treatment of Trypanosoma gambiense infection in Cote d'Ivoire. Trans R Soc Trop Med Hyg 85: 608-611.
44. Brun R, Balmer O (2006). New developments in human African trypanosomiasis. Curr Opin Infect Dis 19: 415-420.
45. Brun R, Schumacher R, Schmid C, Kunz C, Burri C (2001). The phenomenon of treatment failures in human African trypanosomiasis. Trop Med Intl Health 6: 906-914.
46. Buguet A, Bert J, Tapie P, Tabaraud F, Doua F, Lonsdorfer J et al. (1993). Sleep-wake cycle in human African trypanosomiasis. J Clin Neurophysiol 10: 190-196.
47. Buguet A, Bisser S, Josenando T, Chapotot F, Cespuglio R (2005). Sleep structure: a new diagnostic tool for stage determination in sleeping sickness. Acta Trop 93: 107-117.
48. Burri C, Baltz T, Giroud C, Doua F, Welker HA, Brun R (1993). Pharmacokinetic properties of the trypanocidal drug melarsoprol. Chemotherapy 39: 225-234.
49. Burri C, Brun R (1992). An in vitro bioassay for quantification of melarsoprol in serum and cerebrospinal fluid. Trop Med Parasitol 43: 223-225.
50. Burri C, Brun R (2003). Eflornithine for the treatment of human African trypanosomiasis. Parasitology Res 90: S49-S52.
51. Burri C, Keiser J (2001). Pharmacokinetic investigations in patients from northern Angola refractory to melarsoprol treatment. Trop Med Int Health 6: 412-420.
52. Burri C, Nkunku S, Merolle A, Smith T, Blum J, Brun R (2000). Efficacy of new, concise schedule for melarsoprol in treatment of sleeping sickness caused by Trypanosoma brucei gambiense: a randomised trial. Lancet 355: 1419-1425.
53. Burri C, Stich A, Brun R (2004). Current chemotherpay of human African trypanosomiasis. In: Maudlin I, Holmes PH, Miles MA (eds). The Trypanosomiases. CABI: Oxford, pp 403-420.
54. Buscher P, Bin Shamamba SK, Ngoyi DM, Pyana P, Baelmans R, Magnus E et al. (2005). Susceptibility of Grammomys surdaster thicket rats to Trypanosoma brucei gambiense infection. Trop Med Int Health 10: 850-855.
55. Buxbaum E (1999). Co-operative binding sites for transported substrates in the multiple drug resistance transporter Mdr1. Eur J Biochem 265: 64-70.
56. Carter NS, Berger BJ, Fairlamb AH (1995). Uptake of diamidine drugs by the P2 nucleoside transporter in melarsen-sensitive and -resistant Trypanosoma brucei brucei. J Biol Chem 270: 28153-28157.
57. Carter NS, Fairlamb AH (1993). Arsenical-resistant trypanosomes lack an unusual adenosine transporter. Nature 361: 173-176.
58. Castro JA, de Mecca MM, Bartel LC (2006). Toxic side effects of drugs used to treat Chagas' disease (American trypanosomiasis). Hum Exp Toxicol 25: 471-479.
59. Chappuis F, Loutan L, Simarro P, Lejon V, Buscher P (2005a). Options for field diagnosis of human African trypanosomiasis. Clin Microbiol Rev 18: 133-146.
60. Chappuis F, Udayraj N, Stietenroth K, Meussen A, Bovier PA (2005b). Eflornithine is safer than melarsoprol for the treatment of second-stage Trypanosoma brucei gambiense human African trypanosomiasis. Clin Infect Dis 41: 748-751.
61. Clement B (2002). Reduction of N-hydroxylated compounds: amidoximes (N-hydroxyamidines) as pro-drugs of amidines. Drug Metab Rev 34: 565-579.
62. Clement B, Jung F (1994). N-hydroxylation of the antiprotozoal drug pentamidine catalyzed by rabbit liver cytochrome P-450 2C3 or human liver microsomes, microsomal retroreduction, and further oxidative transformation of the formed amidoximes. Possible relationship to the biological oxidation of arginine to NG-hydroxyarginine, citrulline, and nitric oxide. Drug Metab Dispos 22: 486-497.
63. Clement B, Raether W (1985). Amidoximes of pentamidine: synthesis, trypanocidal and leishmanicidal activity. Arzneimittelforschung 35: 1009-1014.
64. Collins JM, Klecker Jr RW, Yarchoan R, Lane HC, Fauci AS, Redfield RR et al. (1986). Clinical pharmacokinetics of suramin in patients with HTLV-III/LAV infection. J Clin Pharmacol 26: 22-26.
65. Conte JE (1991). Pharmacokinetics of intravenous pentamidine in patients with normal renal function or receiving haemodialysis. J Infect Dis 163: 169-175.
66. Coppens I, Courtoy PJ (2000). The adaptative mechanisms of Trypanosoma brucei for sterol homeostasis in its different life-cycle environments. Annu Rev Microbiol 54: 129-156.
67. Croft SL (1999). Pharmacological approaches to antitrypanosomal chemotherapy. Mem Inst Oswaldo Cruz 94: 215-220.
68. Croft SL, Brazil RP (1982). Effect of pentamidine isethionate on the ultrastructure and morphology of Leishmania mexicana amazonensis in vitro. Ann Trop Med Parasitol 76: 37-43.
69. Damper D, Patton CL (1976a). Pentamidine transport and sensitivity in brucei-group trypanosomes. J Protozool 23: 349-356.
70. Damper D, Patton CL (1976b). Pentamidine transport in Trypanosoma brucei - kinetics and specificity. Biochem Pharmacol 25: 271-276.
71. Darsaud A, Chevrier C, Bourdon L, Dumas M, Guguet A, Bouteille B (2004). Megazol combined with suramin improves a new diagnosis index of the early meningo-encephalitic phase of experimental African trypanosomiasis. Trop Med Intern Health 9: 83-91.
72. Das BP, Boykin DW (1977). Synthesis and antiprotozoal activity of 2,5-bis(4-guanylphenyl)furans. J Med Chem 20: 531-536.
73. Davis RH, Lieu P, Ristow JL (1994). Neurospora mutants affecting polyamine-dependent processes and basic-amino-acid transport mutants resistant to the polyamine inhibitor, alpha-difluoromethylornithine. Genetics 138: 649-655.
74. de Koning HP (2001a). Uptake of pentamidine in Trypanosoma brucei brucei is mediated by three distinct transporters: implications for cross-resistance with arsenicals. Mol Pharmacol 59: 586-592.
75. de Koning HP (2001b). Transporters in African trypanosomes: role in drug action and resistance. Int J Parasitol 31: 512-522.
76. de Koning HP, Anderson LF, Stewart ML, Burchmore RJS, Wallace LJM, Barrett MP (2004). The trypanocide diminazene aceturate is accumulated predominantly through the TbAT1 purine transporter: additional insights on diamidine resistance in African trypanosomes. Antimicrob Agents Chemother 48: 1515-1519.
77. Denise H, Barrett MP (2001). Uptake and mode of action of drugs used against sleeping sickness. Biochem Pharmacol 61: 1-5.
78. Docampo R, Moreno SNJ (1986). Free-radical metabolism of antiparasitic agents. Fed Proc 45: 2471-2476.
79. Doua F, Miezan TW, Singaro JRS, Yapo FB, Baltz T (1996). The efficacy of pentamidine in the treatment of early-late stage Trypanosoma brucei gambiense trypanosomiasis. Am J Trop Med Hyg 55: 586-588.
80. Doua F, Yapo FB (1993). Human trypanosomiasis in the Ivory Coast - therapy and problems. Acta Tropica 54: 163-168.
81. Drews J (2004). Paul Ehrlich: Magister Mundi. Nat Rev Drug Discov 3: 797-801.
82. Eisenberger MA, Reyno L (1994). Suramin. Cancer Treat Rev 20: 259-273.
83. El Rayah IE, Kaminsky R, Schmid C, El Malik KH (1999). Drug resistance in Sudanese Trypanosoma evansi. Vet Parasitol 80: 281-287.
84. Enanga B, Burchmore RJ, Stewart ML, Barrett MP (2002). Sleeping sickness and the brain. Cell Mol Life Sci 59: 845-858.
85. Enanga B, Keita M, Chauvière G, Dumas M, Bouteille B (1998). Megazol combined with suramin: a chemotherapy regimen which reversed the CNS pathology in a model of human African trypanosomiasis in mice. Trop Med Int Health 3: 736-741.
86. Enanga B, Ariyanayagam MR, Stewart ML, Barrett MP (2003). Activity of megazol, a trypanocidal nitroimidazole, is associated with DNA damage. Antimicrob Agents Chemother 47: 3368-3370.
87. Enanga B, Ndong JM, Boudra H, Debrauwer L, Dubreuil G, Bouteille B et al. (2000). Pharmacokinetics, metabolism and excretion of megazol in a Trypanosoma brucei gambiense primate model of human African trypanosomiasis. Preliminary study. Arzneimittelforschung 50: 158-162.
88. Engstler M, Thilo L, Weise F, Grunfelder CG, Schwarz H, Boshart M et al. (2004). Kinetics of endocytosis and recycling of the GPI-anchored variant surface glycoprotein in Trypanosoma brucei. J Cell Sci 117: 1105-1115.
89. Erwin BG, Pegg AE (1982). Uptake of alpha-difluoromethylornithine by mouse fibroblasts. Biochem Pharmacol 31: 2820-2823.
90. Fairlamb AH (2003). Chemotherapy of human African trypanosomiasis: current and future prospects. Trends Parasitol 19: 488-494.
91. Fairlamb AH, Blackburn P, Ulrich P, Chait BT, Cerami A (1985). Trypanothione - a novel bis(glutathionyl)spermidine cofactor for glutathione-reductase in trypanosomatids. Science 227: 1485-1487.
92. Fairlamb AH, Bowman IBR (1977). Trypanosoma brucei - suramin and other trypanocidal compounds effects on Sn-glycerol-3-phosphate oxidase. Exp Parasitol 43: 353-361.
93. Fairlamb AH, Bowman IBR (1980). Uptake of the trypanocidal drug suramin by bloodstream forms of Trypanosoma brucei and its effect on respiration and growth-rate in vivo. Mol Biochem Parasitol 1: 315-333.
94. Fairlamb AH, Carter NS, Cunningham M, Smith K (1992a). Characterization of melarsen-resistant Trypanosoma brucei brucei with respect to cross-resistance to other drugs and trypanothione metabolism. Mol Biochem Parasitol 53: 213-222.
95. Fairlamb AH, Henderson GB, Bacchi CJ, Cerami A (1987). In vivo effects of difluoromethylornithine on trypanothione and polyamine levels in blood-stream forms of Trypanosoma brucei. Mol Biochem Parasitol 24: 185-191.
96. Fairlamb AH, Henderson GB, Cerami A (1989). Trypanothione is the primary target for arsenical drugs against African trypanosomes. Proc Natl Acad Sci USA 86: 2607-2611.
97. Fairlamb AH, Le Quesne SA (1997). Polyamine metabolism in trypanosomes. In: Hide G, Mottram JC, Coombs GH, Holmes PH (eds). Trypanosomiasis and Leishmaniasis. CAB International: Oxford, pp 149-161.
98. Fairlamb AH, Smith K, Hunter KJ (1992b). The interaction of arsenical drugs with dihydrolipoamide and dihydrolipoamide dehydrogenase from arsenical resistant and sensitive strains of Trypanosoma brucei brucei. Mol Biochem Parasitol 53: 223-231.
99. Fevre EM, Picozzi K, Fyfe J, Waiswa C, Odiit M, Coleman PG et al. (2005). A burgeoning epidemic of sleeping sickness in Uganda. Lancet 366: 745-747.
100. Friedheim EAH (1949). MelB in the treatment of human trypanosomiasis. Am J Trop Med Hyg 29: 173-180.
101. Frommel TO, Balber AE (1987). Flow cytofluorometric analysis of drug accumulation by multidrug-resistant Trypanosoma brucei brucei and T.b. rhodesiense. Mol Biochem Parasitol 26: 183-191.
102. Gerner EW, Meyskens Jr FL (2004). Polyamines and cancer: old molecules, new understanding. Nat Rev Cancer 4: 781-792.
103. Ghoda L, Phillips MA, Bass KE, Wang CC, Coffino P (1990). Trypanosome ornithine decarboxylase is stable because it lacks sequences found in the carboxyl terminus of the mouse enzyme which target the latter for intracellular degradation. J Biol Chem 265: 11823-11826.
104. Gibaud S, Gaia A, Astier A (2002). Slow-release melarsoprol micro-particles. Int J Pharmacol 243: 161-166.
105. Gibaud S, Zirar SB, Mutzenhardt P, Fries I, Astier A (2005). Melarsoprol-cyclodextrin inclusion complexes. Int J Pharmacol 306: 107-121.
106. Green HP, Del Pilar Molina Portela M, St Jean EN, Lugli EB, Raper J (2003). Evidence for a Trypanosoma brucei lipoprotein scavenger receptor. J Biol Chem 278: 422-427.
107. Griffin CA, Slavik M, Chien SC, Hermann J, Thompson G, Blanc O et al. (1987). Phase I trial and pharmacokinetic study of intravenous and oral alpha- difluoromethylornithine. Invest New Drugs 5: 177-186.
108. Haegele KD, Alken RG, Grove J, Schechter PJ, Koch-Weser J (1981). Kinetics of alpha-difluoromethylornithine: an irreversible inhibitor of ornithine decarboxylase. Clin Pharmacol Therap 30: 210-217.
109. Hall JE, Kerrigan JE, Ramachandran K, Bender BC, Stanko JP, Jones SK et al. (1998). Anti-Pneumocystis activities of aromatic diamidoxime prodrugs. Antimicrob Agents Chemother 42: 666-674.
110. Hanau S, Rippa M, Bertelli M, Dallocchio F, Barrett MP (1996). 6-Phosphogluconate dehydrogenase from Trypanosoma brucei. Kinetic analysis and inhibition by trypanocidal drugs. Eur J Biochem 240: 592-599.
111. Hawking F (1962). Estimation of the concentration of melarsoprol (Mel B) and Mel W in biological fluids by bioassay with trypanosomes in vitro. Trans R Soc Trop Med Hyg 56: 354-363.
112. Hawking FJ, Smiles SJ (1941). The distribution of 4:4′-diamidino stilbene in trypanosomes and mice as shown by fluorescence. Ann Trop Med Parasitol 35: 45-50.
113. Hentzer B, Kobayasi T (1977). The ultrastructural changes of Leishmania tropica after treatment with pentamidine. Ann Trop Med Parasitol 71: 157-166.
114. Ismail MA, Brun R, Easterbrook JD, Tanious FA, Wilson WD, Boykin DW (2003). Synthesis and antiprotozoal activity of aza-analogues of furamidine. J Med Chem 46: 4761-4769.
115. Iten M, Matovu E, Brun R, Kaminsky R (1995). Innate lack of susceptibility of Ugandan Trypanosoma brucei rhodesiense to D,L-alpha-difluoromethylornithine (DFMO). Trop Med Parasitol 46: 190-194.
116. Iten M, Mett H, Evans A, Enyaru JC, Brun R, Kaminsky R (1997). Alterations in ornithine decarboxylase characteristics account for tolerance of Trypanosoma brucei rhodesiense to D,L-alpha- difluoromethylornithine. Antimicrob Agents Chemother 41: 1922-1925.
117. Janssens PG, Demuynck A (1977). Clinical-trials with nifurtimox in African trypanosomiasis. Ann Soc Belg Med Trop 57: 475-480.
118. Jennings FW (1991). Chemotherapy of CNS-trypanosomiasis - the combined use of the arsenicals and nitrocompounds. Trop Med Parasitol 42: 139-142.
119. Jennings FW (1993). Combination chemotherapy of CNS trypanosomiasis. Acta Trop 54: 205-213.
120. Jennings FW (1995). Suramin treatment of experimental Trypanosoma brucei infection of the central nervous system. Trans R Soc Trop Med Hyg 89: 677.
121. Jennings FW, Atouguia JM, Murray M (1993). Topical melarsoprol for trypanosomiasis. Lancet 341: 1341-1342.
122. Jennings FW, Whitelaw DD, Urquhart GM (1977). The relationship between duration of infection with Trypanosoma brucei in mice and the efficacy of chemotherapy. Parasitology 75: 143-153.
123. Joshi PP, Shegokar VR, Powar RM, Herder S, Katti R, Salkar HR et al. (2005). Human trypanosomiasis caused by Trypanosoma evansi in India: the first case report. Am J Trop Med Hyg 73: 491-495.
124. Kaur M, Reed E, Sartor O, Dahut W, Figg WD (2002). Suramin's development: what did we learn? Invest New Drugs 20: 209-219.
125. Keiser J, Stich A, Burri C (2001). New drugs for the treatment of human African trypanosomiasis: research and development. Trends Parasitol 17: 42-49.
126. Kennedy PG (2006). Human African trypanosomiasis-neurological aspects. J Neurol 253: 411-416.
127. Kinabo LDB (1993). Pharmacology of existing drugs for animal trypanosomiasis. Acta Trop 54: 169-183.
128. Kremsner PG, Krishna S (2004). Antimalarial combinations. Lancet 364: 285-294.
129. Lanteri CA, Stewart ML, Brock JM, Alibu VP, Meshnick SR, Tidwell RR et al. (2006). Roles for the Trypanosoma brucei P2 transporter in DB75 uptake and resistance. Mol Pharmacol 70: 1585-1592.
130. Lanteri CA, Trumpower BL, Tidwell RR, Meshnick SR (2004). DB75, a novel trypanocidal agent, disrupts mitochondrial function in Saccharomyces cerevisiae. Antimicrob Agents Chemother 48: 3968-3974.
131. Legros D, Evans S, Maiso F, Enyaru JCK, Mbulamberi D (1999). Risk factors for treatment failure after melarsoprol for Trypanosoma brucei gambiense trypanosomiasis in Uganda. Trans R Soc Trop Med Hyg 93: 439-442.
132. Legros D, Ollivier G, Gastellu-Etchegorry M, Paquet C, Burri C, Jannin J et al. (2002). Treatment of human African trypanosomiasis - present situation and needs for research and development. Lancet Infect Dis 2: 437-440.
133. Levin VA, Csejtey J, Byrd DJ (1983). Brain, CSF, and tumor pharmacokinetics of alpha-difluoromethylornithine in rats and dogs. Cancer Chemother Pharmacol 10: 196-199.
134. Ludewig G, Williams JM, Li Y, Staben C (1994). Effects of pentamidine isethionate on Saccharomyces cerevisiae. Antimicrob Agents Chemother 38: 1123-1128.
135. MacLean L, Chisi JE, Odiit M, Gibson WC, Ferris V, Picozzi K et al. (2004). Severity of human African trypanosomiasis in East Africa is associated with geographic location, parasite genotype, and host inflammatory cytokine response profile. Infect Immun 72: 7040-7044.
136. Maina NW, Kunz C, Brun R (2006). Cryopreservation of Trypanosoma brucei gambiense in a commercial cryomedium developed for bull semen. Acta Trop 98: 207-211.
137. Maina NWN, Oberle M, Otieno C, Kunz C, Maeser P, Ndung'u JM et al. (2007). Isolation and propagation of Trypanosoma brucei gambiense from sleeping sickness patients in South Sudan. Trans Roy Soc Trop Med Hyg (in press).
138. Mäser P, Sutterlin C, Kralli A, Kaminsky R (1999). A nucleoside transporter from Trypanosoma brucei involved in drug resistance. Science 285: 242-244.
139. Mathis AM, Holman JL, Sturk LM, Ismail MA, Boykin DW, Tidwell RR et al. (2006). Accumulation and intracellular distribution of antitrypanosomal diamidine compounds DB75 and DB820 in African trypanosomes. Antimicrob Agents Chemother 50: 2185-2191.
140. Matovu E, Enyaru JCK, Legros D, Schmid C, Seebeck T, Kaminsky R (2001). Melarsoprol refractory T.b. gambiense from Omugo, northwestern Uganda. Trop Med Int Health 6: 407-411.
141. Matovu E, Stewart ML, Geiser F, Brun R, Maser P, Wallace LJM et al. (2003). Mechanisms of arsenical and diamidine uptake and resistance in Trypanosoma brucei. Eukaryot Cell 2: 1003-1008.
142. McCulloch R (2004). Antigenic variation in African trypanosomes: monitoring progress. Trends Parasitol 20: 117-121.
143. Meshnick SR, Blobstein SH, Grady RW, Cerami A (1978). Approach to development of new drugs for African trypanosomiasis. J Exp Med 148: 569-579.
144. Miezan TW, Bronner U, Doua F, Cattand P, Rombo L (1994). Long-term exposure of Trypanosoma brucei gambiense to pentamidine in vitro. Trans R Soc Trop Med Hyg 88: 332-333.
145. Millet R, Maes L, Landry V, Sergheraert C, Davioud-Charvet E (2002). Antitrypanosomal activities and cytotoxicity of 5-nitro-2-furancarbohydrazides. Bioorg Med Chem Lett 12: 3601-3604.
146. Milord F, Loko L, Ethier L, Mpia B, Pepin J (1993). Eflornithine concentrations in serum and cerebrospinal fluid of 63 patients treated for Trypanosoma brucei gambiense sleeping sickness. Trans R Soc Trop Med Hyg 87: 473-477.
147. Mitsuya H, Popovic M, Yarchoan R, Matsushita S, Gallo RC, Broder S (1984). Suramin protection of T cells in vitro against infectivity and cytopathic effect of HTLV-III. Science 226: 172-174.
148. Moens F, Dewilde M, Ngato K (1984). Clinical-trial of nifurtimox in human African trypanosomiasis. Ann Soc Belg Med Trop 64: 37-43.
149. Moore A, Richer M (2001). Re-emergence of epidemic sleeping sickness in southern Sudan. Trop Med Intl Health 6: 342-347.
150. Mukherjee A, Padmanabhan PK, Sahani MH, Barrett MP, Madhubala R (2006). Roles for mitochondria in pentamidine susceptibility and resistance in Leishmania donovani. Mol Biochem Parasitol 145: 1-10.
151. Mutugi MW, Boid R, Luckins AG (1994). Experimental induction of suramin-resistance in cloned and uncloned stocks of Trypanosoma evansi using immunosuppressed and immunocompetent mice. Trop Med Parasitol 45: 232-236.
152. Na-Bangchang K, Doua F, Konsil J, Hanpitakpong W, Kamanikom B, Kuzoe F (2004). The pharmacokinetics of eflornithine (alpha-difluoromethylornithine) in patients with late-stage T.b. gambiense sleeping sickness. Eur J Clin Pharmacol 60: 269-278.
153. Nishimura K, Yanase T, Araki N, Ohnishi Y, Kozaki S, Shima K et al. (2006). Effects of polyamines on two strains of Trypanosoma brucei in infected rats and in vitro culture. J Parasitol 92: 211-217.
154. Njiokou F, Laveissiere C, Simo G, Nkinin S, Grebaut P, Cuny G et al. (2006). Wild fauna as a probable animal reservoir for Trypanosoma brucei gambiense in Cameroon. Infect Genet Evol 6: 147-153.
155. O'Kane RL, Vina JR, Simpson I, Zaragoza R, Mokashi A, Hawkins RA (2006). Cationic amino acid transport across the blood-brain barrier is mediated exclusively by system y+. Am J Physiol Endocrinol Metab 291: 412-419.
156. Pal A, Hall BS, Field MC (2002). Evidence for a non-LDL-mediated entry route for the trypanocidal drug suramin in Trypanosoma brucei. Mol Biochem Parasitol 122: 217-221.
157. Paulos C, Paredes J, Vasques I, Thambo S, Arancibia A, Gonzales-Martin G (1989). Pharmacokinetics of a nitrofuran compound, nifurtimox, in healthy volunteers. Int J Clin Pharmacol Ther Toxicol 9: 454-457.
158. Pays E, Vanhollebeke B, Vanhamme L, Paturiaux-Hanocq F, Nolan DP, Perez-Morga D (2006). The trypanolytic factor of human serum. Nat Rev Microbiol 4: 477-486.
159. Pécoul B, Chirac P, Trouiller P, Pinel J (1999). Access to essential drugs in poor countries: a lost battle? JAMA 281: 361-367.
160. Pepin J, Milord F (1994). The treatment of human African trypanosomiasis. Adv Parasitol 33: 1-47.
161. Pepin J, Milord F, Meurice F, Ethier L, Loko L, Mpia B (1992). High-dose nifurtimox for arseno-resistant Trypanosoma brucei gambiense sleeping sickness: an open trial in central Zaire. Trans R Soc Trop Med Hyg 86: 254-256.
162. Pepin J, Milord F, Mpia B, Meurice F, Ethier L, DeGroof D et al. (1989b). An open clinical trial of nifurtimox for arseno-resistant Trypanosoma brucei gambiense sleeping sickness in central Zaire. Trans R Soc Trop Med Hyg 83: 514-517.
163. Pepin J, Mpia B (2006). Randomized controlled trial of three regimens of melarsoprol in the treatment of Trypanosoma brucei gambiense trypanosomiasis. Trans R Soc Trop Med Hyg 100: 437-441.
164. Pepin J, Milord F, Guerin C, Mpia B, Ethier L, Mansinsa D (1989a). Trial of prednisolone for prevention of melarsoprol-induced encephalopathy in gambiense sleeping sickness. Lancet 1: 1246-1250.
165. Peregrine AS, Mamman M (1993). Pharmacology of diminazene - a review. Acta Trop 54: 185-203.
166. Phillips MA, Coffino P, Wang CC (1987). Cloning and sequencing of the ornithine decarboxylase gene from Trypanosoma brucei. Implications for enzyme turnover and selective difluoromethylornithine inhibition. J Biol Chem 262: 8721-8727.
167. Phillips MA, Coffino P, Wang CC (1988). Trypanosoma brucei ornithine decarboxylase: enzyme purification, characterization, and expression in Escherichia coli. J Biol Chem 263: 17933-17941.
168. Phillips MA, Wang CC (1987). A Trypanosoma brucei mutant resistant to alpha-difluoromethylornithine. Mol Biochem Parasitol 22: 9-17.
169. Priotto G, Fogg C, Balasegaram M, Erphas O, Louga A, Checchi F et al. (2006). Three drug combinations for late-stage Trypanosoma brucei gambiense sleeping sickness: a randomized clinical trial in Uganda. PLoS Clin Trials 1: e39.
170. Rane L, Rane DS, Kinnamon KE (1976). Screening large numbers of compounds in a model based on mortality of Trypanosoma rhodesiense infected mice. Am J Trop Med Hyg 25: 395-400.
171. Raz B, Iten M, GretherBuhler Y, Kaminsky R, Brun R (1997). The Alamar Blue(R) assay to determine drug sensitivity of African trypanosomes (T.b. rhodesiense and T.b. gambiense) in vitro. Acta Trop 68: 139-147.
172. Remme JH, Blas E, Chitsulo L, Desjeux PM, Engers HD, Kanyok TP et al. (2002). Strategic emphases for tropical diseases research: a TDR perspective. Trends Parasitol 18: 421-426.
173. Roberts SC, Jiang Y, Gasteier J, Frydman B, Marton LJ, Heby O et al. (2006). Leishmania donovani polyamine biosynthetic enzyme overproducers as tools to investigate the mode of action of cytotoxic polyamine analogs. Antimicrob Agents Chemother 51: 438-445.
174. Robertson DH (1963). The treatment of sleeping sickness (mainly due to Trypanosoma rhodesiense) with melarsoprol. I. Reactions observed during treatment. Trans R Soc Trop Med Hyg 57: 122-133.
175. Romijn JC, Verkoelen CF, Splinter TA (1987). Problems of pharmacokinetic studies on alpha-difluoromethylornithine in mice. Cancer Chemother Pharmacol 19: 30-34.
176. Ross CA, Barns AM (1996). Alteration to one of three adenosine transporters is associated with resistance to cymelarsan in Trypanosoma evansi. Parasitol Res 82: 183-188.
177. Sands M, Kron MA, Brown RB (1985). Pentamidine - a review. Rev Infect Dis 7: 625-634.
178. Saulter JY, Kurian JR, Trepanier LA, Tidwell RR, Bridges AS, Boykin DW et al. (2005). Unusual dehydroxylation of antimicrobial amidoxime prodrugs by cytochrome b5 and NADH cytochrome b5 reductase. Drug Metab Dispos 33: 1886-1893.
179. Schmid C, Nkunku S, Merolle A, Vounatsou P, Burri C (2004). Efficacy of 10-day melarsoprol schedule 2 years after treatment for late-stage gambiense sleeping sickness. Lancet 364: 789-790.
180. Schmid C, Richer M, Bilenge CM, Josenando T, Chappuis F, Manthelot CR et al. (2005). Effectiveness of a 10-day melarsoprol schedule for the treatment of late-stage human African trypanosomiasis: confirmation from a multinational study (IMPAMEL II). J Infect Dis 191: 1922-1931.
181. Schnaufer A, Domingo GJ, Stuart K (2002). Natural and induced dyskinetoplastic trypanosomatids: how to live without mitochondrial DNA. Int J Parasitol 32: 1071-1084.
182. Scott AG, Tait A, Turner CMR (1996). Characterisation of cloned lines of Trypanosoma brucei expressing stable resistance to MelCy and suramin. Acta Tropica 60: 251-262.
183. Scott AG, Tait A, Turner CMR (1997). Trypanosoma brucei: lack of cross-resistance to melarsoprol in vitro by cymelarsan-resistant parasites. Exp Parasitol 86: 181-190.
184. Shahi SK, Krauth-Siegel RL, Clayton CE (2002). Overexpression of the putative thiol conjugate transporter TbMRPA causes melarsoprol resistance in Trypanosoma brucei. Mol Microbiol 43: 1129-1138.
185. Simo G, Asonganyi T, Nkinin SW, Njiokou F, Herder S (2006). High prevalence of Trypanosoma brucei gambiense group 1 in pigs from the Fontem sleeping sickness focus in Cameroon. Vet Parasitol 139: 57-66.
186. Simpson L (1986). Kinetoplast DNA in trypanosomatid flagellates. Int Rev Cytol 99: 119-179.
187. Smith AB, Esko JD, Hajduk SL (1995). Killing of trypanosomes by the human haptoglobin-related protein. Science 268: 284-286.
188. Stanghellini A, Josenando T (2001). The situation of sleeping sickness in Angola: a calamity. Trop Med Int Health 6: 330-334.
189. Steck EA, Kinnamon KE, Davidson Jr DE, Duxbury RE, Johnson AJ, Masters RE (1982). Trypanosoma rhodesiense: evaluation of the antitrypanosomal action of 2,5-bis(4-guanylphenyl)furan dihydrochloride. Exp Parasitol 53: 133-144.
190. Steinhoff D, Grundmann E (1972). Test for carcinogenicity of nifurtimox on oral and subcutaneous administration to rats. Arzneimittelforschung 22: 1607-1612.
191. Stewart ML, Bueno GJ, Baliani A, Klenke B, Brun R, Brock JM et al. (2004). Trypanocidal activity of melamine-based nitroheterocycles. Antimicrob Agents Chemother 48: 1733-1738.
192. Stewart ML, Krishna S, Burchmore RJS, Brun R, de Koning HP, Boykin DW et al. (2005). Detection of arsenical drug resistance in Trypanosoma brucei with a simple fluorescence test. Lancet 366: 486-487.
193. Sturk LM, Brock JL, Bagnell CR, Hall JE, Tidwell RR (2004). Distribution and quantitation of the anti-trypanosomal diamidine 2,5-bis(4-amidinophenyl) furan (DB75) and its N-methoxy prodrug DB289 in murine brain tissue. Acta Trop 91: 131-143.
194. Szyniarowski P, Bettendorff L, Schweingruber ME (2006). The antitrypanosomal drug melarsoprol competitively inhibits thiamine uptake in mouse neuroblastoma cells. Cell Biol Toxicol 22: 183-187.
195. Trouiller P, Olliaro P, Torreele E, Orbinski J, Laing R, Ford N (2002). Drug development for neglected diseases: a deficient market and a public-health policy failure. Lancet 359: 2188-2194.
196. Truc P, Jamonneau V, N'Guessan P, N'Dri L, Diallo PB, Cuny G (1998). Trypanosoma brucei ssp. and T congolense: mixed human infection in Cote d'Ivoire. Trans R Soc Trop Med Hyg 92: 537-538.
197. Vanhollebeke B, Truc P, Poelvoorde P, Pays A, Joshi PP, Katti R et al. (2006). Human Trypanosoma evansi infection linked to a lack of apolipoprotein L-I. N Engl J Med 355: 2752-2756.
198. Vanschaftingen E, Opperdoes FR, Hers HG (1987). Effects of various metabolic conditions and of the trivalent arsenical melarsen oxide on the intracellular levels of fructose 2,6-bisphosphate and of glycolytic- intermediates in Trypanosoma brucei. Eur J Biochem 166: 653-661.
199. Vansterkenburg ELM, Coppens I, Wilting J, Bos OJM, Fischer MJE, Janssen LHM et al. (1993). The uptake of the trypanocidal drug suramin in combination with low-density lipoproteins by Trypanosoma brucei and its possible mode of action. Acta Trop 54: 237-250.
200. Viode C, Bettache N, Cenas N, Krauth-Siegel R, Chauvière G, Bakalara N et al. (1999). Enzymatic reduction studies of nitroheterocycles. Biochem Pharmacol 57: 549-557.
201. Voogd TE, Vansterkenburg ELM, Wilting J, Janssen LHM (1993). Recent research on the biological activity of suramin. Pharmacol Rev 45: 177-203.
202. Vreysen MJ, Saleh KM, Ali MY, Abdulla AM, Zhu ZR, Juma KG et al. (2000). Glossina austeni (Diptera: Glossinidae) eradicated on the island of Unguja, Zanzibar, using the sterile insect technique. J Econ Entomol 93: 123-135.
203. Waddy BB (1970). Chemoprophylaxis of human trypanosomiasis. In: Mulligan HW (ed). The African Trypanosomiases. Allan & Unwin: London, pp 711-725.
204. Wang MZ, Saulter JY, Usuki E, Cheung YL, Hall M, Bridges AS et al. (2006). CYP4F enzymes are the major enzymes in human liver microsomes that catalyze the O-demethylation of the antiparasitic prodrug DB289 [2,5-bis(4-amidinophenyl)furan-bis-O-methylamidoxime]. Drug Metab Dispos 34: 1985-1994.
205. Werbovetz K (2006). Diamidines as antitrypanosomal, antileishmanial and antimalarial agents. Curr Opin Investig Drugs 7: 147-157.
206. Wierenga RK, Swinkels B, Michels PA, Osinga K, Misset O, Van Beeumen J et al. (1987). Common elements on the surface of glycolytic enzymes from Trypanosoma brucei may serve as topogenic signals for import into glycosomes. EMBO J 6: 215-221.
207. Williamson J (1962). Chemotherapy and chemoprophylaxis of African trypanosomiasis. Exp Parasitol 12: 323-367.
208. Williamson J (1970). Review of chemotherapeutic and chemoprophylactic agents. In: Mulligan HW (ed). The African Trypanosomiases. Allen & Unwin Ltd: London, pp 125-221.
209. Witola WH, Inoue N, Ohashi K, Onuma M (2004). RNA-interference silencing of the adenosine transporter-1 gene in Trypanosoma evansi confers resistance to diminazene aceturate. Exp Parasitol 107: 47-57.
210. Yarlett N, Bacchi CJ (1988). Effect of D,L-alpha- difluoromethylornithine on methionine cycle intermediates in Trypanosoma brucei brucei. Mol Biochem Parasitol 27: 1-10.
211. Yeates C (2003). DB289. Immtech International. iDrug 6: 1036-1093.
212. Yeramian P, Meshnick SR, Krudsood S, Chalermrut K, Silachamroon U, Tangpukdee N et al. (2005). Efficacy of DB289 in Thai patients with Plasmodium vivax or acute, uncomplicated Plasmodium falciparum infections. J Infect Dis 192: 319-322.
213. Zweygarth E, Kaminsky R (1991). Evaluation of D,L-alpha- difluoromethylornithine against susceptible and drug-resistant Trypanosoma brucei brucei. Acta Trop 48: 223-232.